Ionis Pharmaceuticals INC 8-K filings

Ionis Pharmaceuticals reported second quarter 2026 financial results, highlighting strong commercial revenue growth, progress in key drug development programs, and reaffirming its 2026 financial guidance.

Ionis Pharmaceuticals and AstraZeneca announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in ATTR-CM patients did not meet its primary efficacy endpoint.

Ionis Pharmaceuticals received FDA approval for TRYNGOLZA to treat severe hypertriglyceridemia and reduce the risk of acute pancreatitis.

Ionis Pharmaceuticals announced positive long-term hepatic fat fraction data from the CORE-OLE study for olezarsen in patients with severe hypertriglyceridemia.

Ionis Pharmaceuticals announced the appointment of Ludwig N. Hantson to its Board of Directors, effective June 4, 2026, bringing extensive biopharmaceutical leadership experience.

Ionis Pharmaceuticals and partner GSK announced positive Phase 3 results for bepirovirsen, showing significant functional cure rates in chronic hepatitis B patients.

Ionis Pharmaceuticals announced strong first-quarter 2026 financial results, driven by significant revenue growth and progress across its drug pipeline, leading to improved full-year financial guidance.

Ionis Pharmaceuticals announced additional positive results from a pivotal study of zilganersen for Alexander disease, showing stabilization of gait speed and potential improvement in motor function.

Ionis Pharmaceuticals reported strong 2025 financial results, exceeding revenue guidance, driven by successful independent product launches and substantial R&D revenue, while outlining ambitious plans for multiple new product launches and pipeline advancements in 2026.

Ionis Pharmaceuticals announced preliminary 2025 U.S. net product sales for TRYNGOLZA of $105 million, outperforming expectations, and raised its annual peak sales guidance for olezarsen to over $2 billion.

Ionis Pharmaceuticals' partner GSK announced positive topline results from two pivotal Phase 3 studies for bepirovirsen, an investigational treatment for chronic hepatitis B, demonstrating a statistically significant functional cure rate.

Ionis Pharmaceuticals successfully completed a $770 million private offering of 0.00% Convertible Senior Notes due 2030 to refinance existing debt and for general corporate purposes.

Ionis Pharmaceuticals announced positive pivotal Phase 3 CORE and CORE2 study results for olezarsen in severe hypertriglyceridemia, demonstrating significant triglyceride reduction and acute pancreatitis event reduction.

Ionis Pharmaceuticals has entered into an advisory agreement with former executive Richard Geary to ensure continuity of expertise following his retirement.

Ionis Pharmaceuticals reported strong third-quarter 2025 financial results, driven by robust product sales and increased guidance for the full year.

Ionis Pharmaceuticals announced positive topline results from a pivotal study of zilganersen, demonstrating a clinically meaningful and disease-modifying impact on Alexander disease.

Ionis Pharmaceuticals announced positive topline results from pivotal Phase 3 CORE and CORE2 studies for olezarsen, demonstrating significant reductions in triglycerides and acute pancreatitis events in severe hypertriglyceridemia patients.

Ionis Pharmaceuticals announced FDA approval of DAWNZERA (donidalorsen), the first RNA-targeted prophylactic treatment for hereditary angioedema in patients 12 years and older.

Ionis Pharmaceuticals reported robust second-quarter 2025 financial results, with revenue doubling year-over-year, driven by strong TRYNGOLZA sales and increased guidance for the full year.

Ionis Pharmaceuticals, Inc. announced the planned retirement of its Executive Vice President and Chief Development Officer, Dr. Richard Geary, effective January 2026, with Dr. Holly Kordasiewicz appointed to succeed him.

Ionis Pharmaceuticals, Inc. announced that its stockholders approved all four proposals at the virtual 2025 Annual Meeting, including the election of four directors, advisory approval of executive compensation, an increase in the equity incentive plan, and ratification of Ernst & Young LLP as auditors.

Ionis Pharmaceuticals reports positive topline results from the Essence study, showing that olezarsen significantly reduced triglycerides in people with moderate hypertriglyceridemia.

Ionis Pharmaceuticals announces positive Q1 2025 financial results, driven by the successful launch of TRYNGOLZA and increased royalty revenue, leading to an increased 2025 financial guidance.

Ionis Pharmaceuticals grants Ono Pharmaceutical exclusive global rights to develop and commercialize sapablursen for polycythemia vera in a deal worth up to $940 million.

Ionis Pharmaceuticals announces its fourth quarter and full year 2024 financial results, highlighting the first independent launch of TRYNGOLZA, progress with WAINUA, and provides 2025 financial guidance.

The FDA has approved Ionis Pharmaceuticals' Tryngolza (olezarsen) as the first-ever treatment for adults with familial chylomicronemia syndrome (FCS), a rare genetic disorder.

Ionis Pharmaceuticals announced its third quarter 2024 financial results, showcasing revenue growth, pipeline advancements, and increased cash guidance.

Ionis Pharmaceuticals successfully completed a public offering of 11.5 million shares of common stock, raising approximately $500.3 million in gross proceeds.

Ionis Pharmaceuticals has filed a preliminary prospectus supplement for a proposed public offering of common stock, detailing recent business developments and pipeline progress.

Ionis Pharmaceuticals announced its second quarter 2024 financial results, highlighting revenue growth, pipeline advancements, and preparations for upcoming product launches.